Skip to main content

Tezacitabine (C09-1182-736)

Aladdin

Catalog No.
C09-1182-736
Manufacturer No.
T648613-5mg
Manufacturer Name
Aladdin Scientific
Quantity
1
Unit of Measure
EA
Price: $1,165.08
List Price: $1,294.53

Tezacitabine is a cytostatic and cytotoxic antimetabolite and a nucleoside analogue . Tezacitabine irreversibly inhibits the ribonucleotide reductase and interferes with DNA replication and repair . Tezacitabine effectively induces cells apoptotic .

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account.

Adding to cart… The item has been added
Tezacitabine is a cytostatic and cytotoxic antimetabolite and a nucleoside analogue . Tezacitabine irreversibly inhibits the ribonucleotide reductase and interferes with DNA replication and repair . Tezacitabine effectively induces cells apoptotic . Tezacitabine has the potential for leukemias and solid tumors (carcinomas) treatmentIn VitroTezacitabine (0.01-10 µM; 24 hours; CCRF-SB, KG-1, Jurkat, COLO-205, MCF-7 and PC-3 cells) treatment induces the G1 and S-phase leaky block of the cell cycle. Tezacitabine (0.01-10 µM; 24 hours; CCRF-SB, KG-1, Jurkat, COLO-205, MCF-7 and PC-3 cells) treatment apoptotic death of cells by the caspase 3/7 pathway in a concentration-dependent manner. Tezacitabine has strong cytostatic and cytotoxic properties. Cytotoxic effect of Tezacitabine reveals not only as apoptosis, but also as a change in protein metabolism. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cycle AnalysisCell Line: CCRF-SB, KG-1, Jurkat, COLO-205, MCF-7 and PC-3 cells Concentration: 0.01 µM, 0.1 µM, 1.0 µM, and 10 µM Incubation Time: 24 hours Result: Induced the G1 (at concentrations higher than 10 nM) and S-phase (at low concentration) leaky block of the cell cycle. Apoptosis AnalysisCell Line: CCRF-SB, KG-1, Jurkat, COLO-205, MCF-7 and PC-3 cells Concentration: 0.01 µM, 0.1 µM, 1.0 µM, and 10 µM Incubation Time: 24 hours Result: Induced apoptotic death of cells by the caspase 3/7 pathway in a concentration-dependent manner.In VivoTezacitabine (100 mg/kg; intraperitoneal injection; daily; female nude mice) treatment inhibits tumor growth in HCT 116 tumor xenografts. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female nude mice (7-9-week-old) injected with HCT 116 cellsDosage: 100 mg/kg Administration: Intraperitoneal injection; daily; 14 days Result: Inhibited tumor growth in HCT 116 tumor xenografts.Form:SolidIC50& Target:Ribonucleotide reductase. Specification: 0.99 Molecular Formula: C10H12FN3O4 Molecular Weight: 257.22 PubChem CID: 6435808 Isomeric SMILES: C1=CN(C(=O)N=C1N)[C@H]2/C(=C/F)/[C@@H]([C@H](O2)CO)O
UPC:
12352208
Condition:
New
Availability:
8-12 weeks
Weight:
1.06 Ounces
HazmatClass:
No
WeightUOM:
LB
MPN:
T648613-5mg
CAS:
130306-02-4
Product Size:
5mg


Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.


"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."

LAB DIRECTOR


"We utilized Cenmed's capabilities for a variety of projects around the world. They are a valued partner and supplier."

PHARMACEUTICAL SUPPLY CHAIN LEADER


"The reps are very good at finding products for customers in this period of supply chain issues."

SCOTT BEHMAN


"Your customer service has been excellent and makes me excited about purchasing with Cenmed in the future!!"

PROCUREMENT + BILLING COORDINATOR AT PHARMA.